Skip to content

GT Biopharma

10 viewers · 30d

Total raised

$7.2M

3 filings since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity
ROUNDS
3
INVESTORS
6
FOUNDED
N/A
HQ
San Francisco, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
10

AI overview

Updated

GT Biopharma, Inc. is a clinical stage biopharmaceutical company dedicated to the advancement of immunotherapy treatments for cancer and other serious diseases. By focusing on the limitations of existing treatments, GT Biopharma aims to provide innovative solutions that are both targeted and effective.

What sets it apart

GT Biopharma distinguishes itself through its proprietary TriKE platform, which enhances the cancer-fighting abilities of a patient's own natural killer (NK) cells, offering a potentially more effective treatment modality compared to traditional therapies.

Funding history

3 rounds
EquityMay 14, 2025
Form D
—$7.2M total
Equity+2May 12, 2025
Form D
+$6.0M$7.2M total
Equity+2Feb 25, 2025
Form D
+$1.3M$1.3M total

Products

1 tracked

GTB-3650

Immunotherapy

GTB-3650 is a TriKE therapeutic agent specifically targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The product is designed to engage the patient’s immune cells to more effectively target and kill cancer cells, thereby enhancing the therapeutic prospects for patients with challenging forms of blood cancer.

  • Tri-specific engaging mechanism
  • Targets CD33-expressing cells
  • Harnesses patient’s own NK cells
  • Currently in Phase 1 clinical trials

Links

WebsiteSEC EDGAR filings